Selectis Health Inc owns and operates medical care facilities in the healthcare industry... Show more
GBCS broke above its upper Bollinger Band on June 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 21 similar instances where the stock broke above the upper band. In of the 21 cases the stock fell afterwards. This puts the odds of success at .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 58 cases where GBCS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The 50-day moving average for GBCS moved below the 200-day moving average on June 18, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for GBCS entered a downward trend on June 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on May 30, 2025. You may want to consider a long position or call options on GBCS as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for GBCS just turned positive on June 03, 2025. Looking at past instances where GBCS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
GBCS moved above its 50-day moving average on June 26, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GBCS crossed bullishly above the 50-day moving average on June 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where GBCS advanced for three days, in of 34 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GBCS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GBCS's P/B Ratio (86.957) is very high in comparison to the industry average of (4.275). P/E Ratio (17.182) is within average values for comparable stocks, (75.451). GBCS's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.595). GBCS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.025). P/S Ratio (0.409) is also within normal values, averaging (9.290).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GBCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices